Skip to content

News
Careers
Locations
Contact Us

Choose region
- Global
- United States

Choose region
- Global
- United States

Report Adverse Event

About Us
About Us

Helsinn is a global pharmaceutical company.
Mission, Vision and Values

Leadership

Our Story

Our Global Reach
Products
Products

We provide products that improve the lives of patients with cancer and chronic diseases.
Akynzeo®

Aloxi® Onicit® Paloxi®

Arokaris®

Adlumiz®

Valchlor®/Ledaga®

Aulin® Mesulid® Nisulid®
Business
Business

Helsinn operates a unique integrated licensing business model.
Our Business Model

Business Development

In-Licensing

Partnering

Our Partnerships
Technology
Technology

We have a comprehensive technical organization.
Manufacturing and Supply

Life-Cycle Development

Research Grants
ESG
ESG

We’re advancing ESG initiatives that contribute to our sustainable growth.
Sustainability

Carbon Neutral Company

Ethics and Governance

Codes of Conduct and Ethics

Reporting Channels

Compliance

Clinical Data Sharing Governance
Patients
Patients

Our mission is to improve the lives of patients all over the world.
Commitment to Patients

Early Access Programs

Educational Grants

Report Adverse Event

About Us
Products
Business
Technology
ESG
Codes of Conduct and Ethics
Patients

News
Careers
Locations
Contact Us

Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes

News
13/01/2022

Linkedin X-twitter Vimeo

Products
Business
Technology
Patients

Choose region
- Global
- United States

Choose region
- Global
- United States

Helsinn Healthcare SA. All rights reserved. Helsinn Group 2025 ©

Privacy and Cookies Policy
Pharmacovigilance Data Privacy Policy
Terms of Use
Cookie Settings

Search

Exiting the US site

You are about to enter a website not intended for a US audience.
Please confirm your acceptance to continue

Entering the US site

You are about to enter a website only intended for a US audience.
Please confirm your acceptance to continue.

You are now leaving helsinn.com

Please click ‘Continue to external site’ if you want to continue.

Continue to external site